Drug Trial Radar · NCT00693849
International Study to Predict Optimised Treatment - in Depression
Last checked: Nov 20, 2026Latest source record: Jul 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,688
Planned (sponsor's estimate)
Start
Sep 2008
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- BRC Operations Pty. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.
Conditions
- Major Depressive Disorder
Interventions
EscitalopramDrug
10 mg/day as a single dose, increased to max 20 mg/day
SertralineDrug
50 mg/day as a single dose, increased to max of 200 mg/day
Venlafaxine-XRDrug
75 mg/day given once daily; increased to 150-225 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDDTime frame: Week 8
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Shanti Clinical Trials
Colton, California
A.D.D. Treatment Center
Mission Viejo, California
Stanford University
Stanford, California
Veteran Affairs/Stanford University
Stanford, California
Center for Healing the Human Spirit
Tarzana, California
University of Miami
Miami, Florida
University of Missouri - St. Louis
St Louis, Missouri
Brain Resource Center
Englewood Cliffs, New Jersey
Brain Resource Center
New York, New York
Weill Cornell Medical College
White Plains, New York
Skyland Behavioral Health Associates , P.A.
Asheville, North Carolina
Ohio State University
Columbus, Ohio
NeuroDevelopment Center
Providence, Rhode Island
Brain Dynamics Centre
Westmead, New South Wales, Australia
Flinders University
Adelaide, South Australia, Australia
Swinburne University
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Brainclinics Diagnostics B.V.
Nijmegen, Gelderland, Netherlands
University of Auckland
Auckland, New Zealand
Brain Health Lab
Johannesburg, Guatang, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.